Patterns of Acute Myocardial Infarction in Taiwan from 2009 to 2015

Lee, Cheng‐Han; Fang, Ching Chang; Tsai, Liang Miin; Gan, Shu Ting; Lin, Sheng Hsiang; Li, Yi Heng

doi:10.1016/j.amjcard.2018.08.047

Cited by 30 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PLATO study showed that patients with ACS receiving DAPT with ticagrelor had significantly better cardiovascular outcomes than those receiving DAPT with clopidogrel [11]. Ticagrelor was introduced to Taiwan in 2013 and gradually became the first-line P2Y12 inhibitor for ACS [12]. Currently, clopidogrel is mainly used for patients with a high bleeding risk, such as old age, low body weight, concomitant use of oral anticoagulant, and prior major bleeding history [3].…”

Section: Introductionmentioning

confidence: 99%

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Chen

Feng

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Background: P2Y12 inhibitor monotherapy is an alternative antiplatelet strategy in patients undergoing percutaneous coronary intervention (PCI). However, the ideal P2Y12 inhibitor for monotherapy is unclear. Methods and Results: We performed a multicenter, retrospective, observational study to compare the efficacy and safety of monotherapy with clopidogrel versus ticagrelor in patients with acute coronary syndrome (ACS) undergoing PCI. From 1 January 2014 to 31 December 2018, 610 patients with ACS who received P2Y12 monotherapy with either clopidogrel (n = 369) or ticagrelor (n = 241) after aspirin was discontinued prematurely were included. Inverse probability of treatment weighting was used to balance covariates between the groups. The primary endpoint was the composite of all-cause mortality, recurrent ACS or unplanned revascularization, and stroke within 12 months after discharge. Overall, 84 patients reached the primary endpoint, with 57 (15.5%) in the clopidogrel group and 27 (11.2%) in the ticagrelor group. Multivariate adjustment in Cox proportional-hazards models revealed a lower risk of the primary endpoint with ticagrelor than with clopidogrel (adjusted hazard ratio (aHR): 0.67, 95% confidence interval (CI): 0.49–0.93). Ticagrelor significantly reduced the risk of recurrent ACS or unplanned revascularization (aHR: 0.46, 95% CI: 0.28–0.75). No significant difference in all-cause mortality and major bleeding events was observed between the 2 groups. Conclusions: Among patients with ACS undergoing PCI who cannot complete course of dual antiplatelet therapy, a significantly lower risk of cardiovascular events was associated with ticagrelor monotherapy than with clopidogrel monotherapy. The major bleeding risk was similar in both the groups.

show abstract

Section: Introductionmentioning

confidence: 99%

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Chen

Feng

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, the annual age-standardized incidence rate of diabetes was <1% across Taiwanese population (Jiang et al, 2012). Additionally, the age and gender-adjusted incidence of AMI was 50.7/100,000 persons in 2015 (Lee et al, 2018) and the estimated stroke incidence was 12.3/1000 person-years (Chan et al, 2018). Our results highlight the need for studies to determine the impact of TB disease on risk of NCDs; such studies will require substantial follow-up time and a control group without TB disease.…”

Section: Discussionmentioning

confidence: 99%

Post-tuberculosis incidence of diabetes, myocardial infarction, and stroke: Retrospective cohort analysis of patients formerly treated for tuberculosis in Taiwan, 2002–2013

Salindri

Wang

Lin

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objectives:To estimate the incidence of diabetes, acute myocardial infarction (AMI), and stroke; and to determine factors associated with diabetes, AMI, and stroke incidence among patients previously treated for tuberculosis (TB) disease.Methods:A retrospective cohort study was conducted among non-pediatric TB patients registered in the Taiwan National Health Insurance Research Database (NHIRD) from 2002–2013. Diabetes, AMI, and stroke incidence were defined by International Classification of Diseases (ICD)-9 codes, drug prescriptions, and records of patient’s clinic visits. Cox proportional hazard models were used to estimate the hazard rate ratio (HR) of incident diabetes, AMI, and stroke.Results:From 2002–2013, there were 157,444 patients treated for TB registered in NHIRD. Among 129,453 patients with no prior history of diabetes, the age-adjusted incidence rate (IR) of diabetes was 3.85 (95%CI 3.70–4.01) per 1000 person-years. Among 143,646 patients with no prior history of AMI, the age-adjusted IR of AMI as 3.26 (95%CI 3.13–3.40). Among 118,774 patients with no prior history of stroke, the age-adjusted IR of stroke was 16.08 (95%CI 15.76–16.32).Conclusions:Chronic non-communicable disease risk factors like dyslipidemia, hypertension, and chronic kidney disease diagnosed before time of TB diagnosis were predictive of diabetes, AMI, and stroke incidence.

show abstract

“…As for long‐term prognosis, conclusions are inconsistent and studies are few 4‐6 . We know that women before menopause are protected by estrogen and tend to have less CV disease, but as previously reported, younger women have an increased incidence of MI and a higher mortality rate than do men 2,7,8 . Taiwan's National Health Insurance Research Database (NHIRD) was used to investigate sex differences in in‐hospital and long‐term CV outcomes in patients with AMI.…”

Section: Introductionmentioning

confidence: 99%

“…Most studies in this area point to higher overall and CV mortality among hospitalized female patients with MI. 2,3 As for long-term prognosis, conclusions are inconsistent and studies are few. [4][5][6] We know that women before menopause are protected by estrogen and tend to have less CV disease, but as previously reported, younger women have an increased incidence of MI and a higher mortality rate than do men.…”

mentioning

confidence: 99%

Sex differences in long‐term cardiovascular outcomes among patients with acute myocardial infarction: A population‐based retrospective cohort study

Chang

Lin

Chen

et al. 2021

Int. J. Clin. Pract.

View full text Add to dashboard Cite

Background: Whether a sex difference exists in long-term cardiovascular (CV) outcomes after acute myocardial infarction (AMI) is worth exploration. This study is sought to investigate the relationships among sex, age, and the long-term prognosis after AMI. Methods: This population-based retrospective cohort study used Taiwan's NationalHealth Insurance Research Database to investigate the sex differences in in-hospital and long-term CV outcomes in patients with AMI. We enrolled patients who were first diagnosed with AMI from January 1, 2000 to December 31, 2013. The outcomes of interest included all-cause mortality, CV death, non-fatal stroke, non-fatal heart failure, and AMI recurrence during hospitalization and 5-year follow up. The CV outcomes were also analyzed by age stratification.Results: Overall, 201 921 patients with AMI were analyzed; 68.72% were men and 31.28% were women, with mean ages of 65.34 ± 14.12 and 73.05 ± 12.22 years, respectively. Major adverse cardiac events during hospitalization and up to 5 years were consistently greater in women than in men. Multivariable regression analysis revealed no sex difference existed in long-term all-cause and CV mortality. Men of all age groups consistently showed higher risk of both short-and long-term recurrence of AMI. Nonetheless, the female sex still independently predicted increased risk of non-fatal stroke and heart failure from hospitalization until 3-year follow up. Conclusion:Women with AMI had poorer short-term and long-term outcomes. The sex differences in long-term all-cause and CV death disappear after multivariate analysis. Nonetheless, female AMI patients independently predicted higher risk of stroke and heart failure from hospitalization until a 3-year follow-up. To better understand the pathophysiology of female patients with AMI and develop more effective management, more studies in this field are necessary in the future. | INTRODUC TI ONAcute myocardial infarction (AMI) is one of the most dangerous cardiovascular (CV) diseases, and its long-term prognosis is usually poor.In recent years, with the development of research on and treatment of atherosclerotic CV disease, the death rate of myocardial infarction (MI) at the acute phase has decreased significantly. 1 Because women have traditionally been thought to have less CV disease compared with men, whether a sex difference exists in the prognosis of patients with MI in the acute and long-term stages has always How to cite this article: Chang S-S, Lin S-Y, Lai J-N, et al. Sex differences in long-term cardiovascular outcomes among patients with acute myocardial infarction: A populationbased retrospective cohort study. Int J Clin Pract.

show abstract

Patterns of Acute Myocardial Infarction in Taiwan from 2009 to 2015

Cited by 30 publications

References 24 publications

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Post-tuberculosis incidence of diabetes, myocardial infarction, and stroke: Retrospective cohort analysis of patients formerly treated for tuberculosis in Taiwan, 2002–2013

Sex differences in long‐term cardiovascular outcomes among patients with acute myocardial infarction: A population‐based retrospective cohort study

Contact Info

Product

Resources

About